Details

Autor(en) / Beteiligte

• Cano Alonso, M
• Planas-Giner, A
• Almendros-Abad, N
• Sosa-Pons, A
• Cardona Roca, L
• Coronel Cordero, L
• Roig Soronellas, M
• Rudi Sola, N

Titel

6ER-025 Effectiveness and safety of 20% autologous serum eye drops in patients with corneal surface pathologies

Ist Teil von

• European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A167-A167

Ort / Verlag

London: British Medical Journal Publishing Group

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Background and ImportanceAutologous serum eye drops (SAED), a pharmaceutical formulation prepared from patient’s blood, are used in corneal surface pathologies. Since alternative therapies are limited, its prescription has increased in recent years.Aim and ObjectivesAnalyse effectiveness and safety of SAED in patients diagnosed with corneal surface pathologies.Material and MethodsObservational, retrospective study in a secondary hospital between January 2019 and March 2022 including patients treated with 20% SAED.Variables: demographic data, diagnose, concomitant diseases, duration of treatment, ocular affectation (left eye (LE), right eye (RE), both eyes (BE)), subjective clinical improvement (SCI), adverse effects (AE), concomitant treatments, visual acuity (VA) at months 0, 3 and 6 of treatment.Effectiveness was evaluated by SCI and VA, measured on a decimal scale, at three and six months of treatment. Safety was evaluated by AE documented in medical records.ResultsThirty-five patients (77% women) were included with mean age 61 years (20-96). Principals diagnoses were: dry eye syndrome (n=15), superficial punctuate keratitis (n=10) and Sjögren’s syndrome (n=9). Forty-eight percent of patients presented concomitant diseases, highlighting fibromyalgia in six of them.Mean treatment length was 500 ± 348 days. Ten patients (28%) discontinued treatment during the study. The reasons were: reaction to 20% SAED (n=4), remission (n=4), death not associated with the treatment (n=1) and change of hospital (n=1).Twenty-nine patients (82%) had affectation in BE. SCI was observed in 82% of patients at months three and six. Principals AE were: conjunctival hyperaemia (n=4), blepharitis (n=2), stinging (n=1) and tears with excess mucus (n=1). Artificial tears (51%) and corticosteroids eye drops (11%) were the main concomitant treatments.VA data was available in 14 patients (40%). Mean VA in RE was 0.80 ± 0.29, 0.80 ± 0.31 and 0.82 ± 0.25 at months 0,3 and 6 respectively. Mean VA in LE was 0.85 ± 0.25, 0.83 ± 0.23 and 0.87 ± 0.15 respectively.Conclusion and RelevanceAccording to SCI and VA’s progressive improvement over the months and a low incidence of AE, 20% SAED are an effective and safe treatment for corneal surface pathologies.References and/or AcknowledgementsConflict of InterestNo conflict of interest.